Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prevalence of HER-2-Positive Invasive Breast Cancer: A Systematic Review from Iran

  • Keyhani, Elahe (Genetics Research Center, University of Social Welfare and Rehabilitation Sciences) ;
  • Muhammadnejad, Ahad (Genetics Research Center, University of Social Welfare and Rehabilitation Sciences) ;
  • Karimlou, Masoud (Biostatistics Department, University of Social Welfare and Rehabilitation Sciences)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The HER-2/neu gene is altered in 15-20% of breast cancer patients. Immunohistochemistry (IHC) is considered to be the most cost-effective method for HER-2 detection in many countries. Approximately 8,000 new cases of breast cancer are observed annually in Iran. The aims of this study were to conduct a systematic review of the literature on the rate of HER-2-positive breast cancer diagnosed by IHC in Iran. Methods: A systematic search of the medical literature using the Medline/PubMed, ISI and SID databases revealed articles published in the English and Persian languages evaluating HER-2-positive breast cancer in Iran. Results: From 22 studies, 3,033 patients were evaluated, of whom 1,350 were diagnosed as HER-2-positive by IHC HER-2 testing. The mean percentage of HER-2-positive patients was 44.5%, which is higher than that recorded in international statistics. Results of this meta-analysis showed a significant heterogeneity between ratios. There was a statistically significant difference between the results of pre- and post implementation of 2007 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline. IHC HER-2 testing has been performed in Iran for over 10 years. Similar to many other countries, before establishment of an infrastructure for IHC diagnostic tests, HER-2 testing was routinely performed in Iran. Our study showed that the statistics reported from Iran varied widely; for instance, the rate of HER-2-positive cases varied from 23.3% to 81.0%. Conclusions: Our results demonstrate that the lack of standardization and harmonization of this test have led to marked variations in breast cancer diagnosis in Iran.

Keywords

References

  1. Academy of Medical of Malaysia (2010). Clinical Practice Guidelines(CPGs). Management Breast Cancer. http://www.moh.gov.my/cpgs.
  2. Afshar Moghaddam N, MahsoniP, Rajabi P, Pooyan Tabibi A (2008). Correlation of Her-2/Neu and Tp53 Expressions with Clinicopathologic Characteristics in Infiltrative Ductal Breast Carcinomas. Iranian J Pathology, 3, 75-80
  3. Albanell J, Andreu X, et al (2009). Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol, 11, 363-75 https://doi.org/10.1007/s12094-009-0370-6
  4. Alizadeh SA, Moshfeghi K, Kalantari M, Ebrahimi Kh (2010). Lymph-node involvement and tumor markers in patients with breast Cancer. Arak Med University J, 12, 44-50
  5. Amouzegar Hashemi F, Alaleh A, Kazemian A, Haddad P (2010). Local recurrence after breast conserving surgery in breast cancer: a study in Cancer Institute, Tehran. Tehran University Med J, 67, 863-9
  6. Antonio C Wolff, M Elizabeth H Hammond, et al (2007). American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast Cancer. J Clin Oncol, 25, 118-45
  7. Arafah M (2012). Correlation of hormone receptors with her 2/ neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia. Turk Patoloji Derg, 28, 38-43
  8. Attarian H, Pirzadeh A, Rezvani H, et al (2011). Clinicopathologic manifestations of Iranian patients with breast cancer. Pak J Med Sci, 27, 182-5
  9. Barberis M, Pellegrini C, Cannone M, et al (2008). Quantitative PCR and HER2 testing in breast cancer a technical and cost-effectiveness analysis. Am J Clin Pathol, 129, 563-70 https://doi.org/10.1309/1AKQDQ057PQT9AKX
  10. Carlson RW, Moench SJ,One author et al (2006). HER2 testing in breast cancer: NCCN task force report and recommendations. J Natl Compr Canc Netw, 4,1-22 https://doi.org/10.6004/jnccn.2006.0001
  11. Chandarlapaty S, Modi Sh, Sloan-Kettering M (2011). Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs? J Clin Oncol, 10;29(23):3111-Ahn ER, https://doi.org/10.1200/JCO.2011.36.4091
  12. Dendukuri N, Khetani K, McIsaac M, Brophy J (2007). Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ, 176, 1429-33 https://doi.org/10.1503/cmaj.061011
  13. El-A Helal T, Khalifa A, Kamel AS (2000). Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt. Anticancer Res, 20, 2145-50
  14. Elkin EB, Weinstein MC, Winer EP, et al (2004). HER-2 testing and Trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol, 22, 854-63 https://doi.org/10.1200/JCO.2004.04.158
  15. Ensani F, Kargar M, Davanloo M, Irvanloo G, Khazaeipour Z (2010). Comparison between Immunohistochemistry and Chromogenic in Situ Hybridization Method in Assessment of HER-2 Status in Breast Cancer. Iranian J Surgery, 7, 8-16
  16. Espinosa AB, Tabernero MD, Garcia-Macias MC, et al (2003). Her-2/neu Gene Amplification in Familial vs Sporadic Breast Cancer. Am J Clin Pathol, 120, 917-27 https://doi.org/10.1309/5H778W5K75CMM03W
  17. Fattahi MG, Mojtahedi Z, Karimaghaee N, et al (2009). Analysis of BRCA1 and BRCA2 mutations in Southern Iranian breast cancer patients. Arch Iran Med, 12, 584-7
  18. Ghaffari SR, Sabokbar T, Dastan J, Rafati M, Moossavi Sh (2011). Her 2 Amplification Status in Iranian Breast Cancer Patients: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridisation (FISH). Asian Pac J Prev, 12, 1031-4.
  19. Gown AM, Goldstein LC, Barry TS, et al (2008). High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol, 21, 1271-7 https://doi.org/10.1038/modpathol.2008.83
  20. Gown AM (2008). Current issues in ER and HER2 testing by IHC in Breast Cancer. Mod Pathol, 21, 8-15 https://doi.org/10.1038/modpathol.2008.34
  21. Halimi M, Aghbali A, Tabrizi D, Olad Sahebmadarek E (2011). Expression of epidermal Growth Factor Receptor Tyrosine Kinase Family in Fine Needle Aspiration and permanent Specimens of Invasive Lobular and Ductal Breast cancer. Pak J Biol Sci, 14, 584-9 https://doi.org/10.3923/pjbs.2011.584.589
  22. Harirchi I, Kolahdoozan S, Karbakhsh M, et al (2011).Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncology. 22, 93-7 https://doi.org/10.1093/annonc/mdq303
  23. Homaei-shandiz F, Ghavam naseri MR, Sharifi N, et al (2006). Evaluation of the Relationship Between Human Epidermal Growth factor receptore-2/neu (c-erbB-2) Amplification and pathologic Grading in Patterns with Breast Cancer. Saudi Med J, 27, 1810-4
  24. Hudis CA, MD (2007). Trastuzumab -Mechanism of Action and Use in Clinical Practice. N engl J med, 357, 39-51 https://doi.org/10.1056/NEJMra043186
  25. Jeremy St. J. Thomas (2009). Quality Assurance in Her-2 Testing-Redefining the Gold Standard. Clin Chem, 55, 1265-7 https://doi.org/10.1373/clinchem.2009.126219
  26. Kadivar M, Askarzadeh P, Shayanfar N, Sadeghipour AR, Bahraminejad M (2009). Interpretation of immunohistochemistry results of HER2/neu expression in invasive breast cancer: evaluation of Interobserver and Intraobserver Agreement. Razi J Medical Science, 16, 147-55
  27. Kadivar M, Esmaili A, Joolaee A (2010). evaluation of microvessel density and vascular endothelial growth factor in invasive breast carcinoma via immunohistochemistry and their correlation with clinicopathologic parameters. Razi J Medical Sci, 16, 46-56
  28. Kadivar M, Rezaee M, Jadidfard R, Joulaee A (2010). Evaluation of histopathology and biologic markers in premenopausal (under 40 years) and postmenopausal (over 60 years) women with breast cancer in hazrat-e-rasoul and atieh hospitals. Razi J Medical Sci, 17, 49-57
  29. Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE (2010). Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. a SEER analysis. Kakarala et al. BMC Cancer, 10, 2-8 https://doi.org/10.1186/1471-2407-10-2
  30. Kuo SJ, Wang BB, Chang CS et al (2007). Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/NEU status in Taiwanese breast cancer patients. Taiwan J Obstet Gynecol, 46, 146-53 https://doi.org/10.1016/S1028-4559(07)60008-4
  31. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidi JP (2008). Multiple-treatments meta-analysis of chemotherapyand targeted therapies in advanced breast cancer. J Natl Cancer Inst, 100, 1780 -91 https://doi.org/10.1093/jnci/djn414
  32. Mechanized system of breast cancer management Iran (2011). http://bcancer.ir. (Persian)
  33. Mirmalek S.A, Tirgary F, Alizadeh HR (2005). Study and comparison between malignant breast tumors and related surounding benign tissue about HER-2 Receptor Persistence. Iranian J surgery, 13
  34. Mirzaei HR, Sabahat A, Nasrollahi F, Mohammadi-Yeganeh L (2010). Correlation between ER, PR, HER2 receptors and prognostic factors in breast cancer. Pejouhandeh, 15, 152-6
  35. Mofid B, Jalali NMR, Kian L, Zayeri F (2004). Association of HER2 With prognostic factors of breast cancer. J the Faculty of Med, 28, 29-32
  36. Moghadaszadeh M, Nikanfar AR, Hemati MR, Gharibi B, Sardashti S (2010). Interaction between Her-2 and Hormone Receptor in Breast Cancer. International J Hematology Oncology and Stem cells Res, 4, 14-16
  37. Mohammadizadeh F, Ghasemibasir HR, Rajabi P, et al (2009). Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma. Cancer Biomark, 5, 1-8 https://doi.org/10.3233/CBM-2009-0551
  38. Montgomery KG, Gertig DM, Baxter SW, et al (2003). The HER2 I655V Polymorphism and Risk of Breast Cancer in Women_ Age 40 Years. Cancer Epidemiology, Biomarkers and Prevention, 12, 1109-11
  39. Moore S (2012). Heart failure in a breast cancer survivor. Oncol Nurs Forum, 39, 147-50 . https://doi.org/10.1188/12.ONF.147-150
  40. Moradi-Marjaneh M, Homaei-Shandiz F, Shamsian SAA, Eftekhar-Zadeh Mashhadi I, Hedayati-Moghadam MR (2008). Correlation of HER2/neu Over Expression, p53 Protein Accumulation and Steroid Receptor Status with Tumor Characteristics: An Iranian Study of Breast Cancer Patients. Iranian J Publ Hlth, 37, 19-28
  41. Mousavi SM, Montazeri A, Mohagheghi MA et al (2007). Breast cancer in iran: an epidemiological review. Breast J, 13, 383-91 https://doi.org/10.1111/j.1524-4741.2007.00446.x
  42. Naeem M, Nadim Khan, Aman Z et al (2008). Pattern of breast cancer: experience at lady reading hospital, peshawar. J Ayub Med Coll Abbottabad. 20, 22-5
  43. Naghshvar F, Torabizade ZH, Emadian O, Zareh A, Ghahramani M (2007). Status of estrogen, progesterone receptors and HER-2/neu expression in invasive breast cancer. J Gorgan university Medical Sci, 8, 65-68
  44. Pourzand A, Fakhree MBA, Hashemzadeh Sh, Halimi M, Daryani A (2011). Hormone Receptor Status in Breast Cancer and its Relation to Age and Other Prognostic Factors. Breast Cancer, 5,87-92
  45. Rabiee Hashemi SM, Rabiee Hashemi S (2008). HER-2, P53 and hormonal receptors protein expression as predictive factors in breast cancer prognosis. Chin J Clin Oncol, 5, 413-7 https://doi.org/10.1007/s11805-008-0413-8
  46. Saatee S, Afrakhteh M, Sadrolhefazi B (2006). High Prevalence of HER-2/ neu overexpression among Iranian women with breast cancer: True or False? Breast J, 12 ,499-501 https://doi.org/10.1111/j.1075-122X.2006.00315.x
  47. Salimi M, Mozdarani H, Majidzadeh K (2012). Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients. Med Oncol, 29, 1502-9 https://doi.org/10.1007/s12032-011-0043-5
  48. Shahriari Ahmadi A, Ghavamzadeh A, Amiri N et al (2005). Clinical, biological and pathological characteristics of breast cancer patients at the taleghani university hospital in kermanshah, Iran. IJHOBMT, 2, 6-11
  49. Shamsalinia A, Keihanian Sh, Ghaffari F, Mansore Saravi M, Najafi Ashtian M (2010). Association between expression of her-2/neu gene and estrogen receptors, progesterone receptors and p53 gene among female with primary breast cancer. The Iranian J Obstetrics, Gynecology and Infertility, 13, 43-48
  50. Sirati F, Ghahhari.A, Alavi N (2009). Determination of the Prevalence of Prognostic factors(HER-2/neu, P53, PR, ER) in breast cancer and assessment of their correlation with each others and age and menopause state of patients. Iranian J of breast disease, 1, 24-31
  51. Smith I, Procter M, et al (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 396, 29-36
  52. Vogel CL (2012). Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat, 131, 371-83 https://doi.org/10.1007/s10549-011-1781-y
  53. World Bank (2010). Gross domestic product World Development Indicators database. http://www.worldbank.org.; Accessed 1 July 2011
  54. Yip CH, Smith RA, et al (2008). Guideline implementation for breast healthcare in low-and middle-income countries. Cancer, 113, 2221-43 https://doi.org/10.1002/cncr.23844

Cited by

  1. gene status and association of clinicopathological variables with it in invasive breast cancer patients vol.124, pp.5, 2016, https://doi.org/10.1111/apm.12518